Screening for AMPA receptor auxiliary subunit specific modulators

• Published in: PloS one Vol. 12; no. 3; p. e0174742
• Main Authors: Azumaya, Caleigh M., Days, Emily L., Vinson, Paige N., Stauffer, Shaun, Sulikowski, Gary, Weaver, C. David, Nakagawa, Terunaga
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 30.03.2017; Public Library of Science (PLoS)
• Subjects: Allosteric properties; Amyotrophic lateral sclerosis; Biological Transport; Biology; Biology and Life Sciences; Biophysics; Brain; CACNG2 protein; Calcium; Calcium - metabolism; Calcium channels (voltage-gated); Calcium Channels - metabolism; Central nervous system; Cloning; Electrophysiology; Genetic aspects; HEK293 Cells; High-throughput screening; Humans; Ion channels; Ligands; Medical screening; Medicine; Medicine and Health Sciences; Membranes; Mental depression; Nervous system diseases; Neurological diseases; Neuromodulation; Neurosciences; Pharmacology; Physicians; Physiology; Receptors, AMPA - metabolism; Research and analysis methods; Side effects; Synaptic plasticity; Synaptic transmission; Transcription (Genetics); α-Amino-3-hydroxy-5-methyl-4-isoxazole propionic acid; α-Amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors; United States > US; Tennessee; Nashville Tennessee
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0174742

AMPA receptors (AMPAR) are ligand gated ion channels critical for synaptic transmission and plasticity. Their dysfunction is implicated in a variety of psychiatric and neurological diseases ranging from major depressive disorder to amyotrophic lateral sclerosis. Attempting to potentiate or depress AMPAR activity is an inherently difficult balancing act between effective treatments and debilitating side effects. A newly explored strategy to target subsets of AMPARs in the central nervous system is to identify compounds that affect specific AMPAR-auxiliary subunit complexes. This exploits diverse spatio-temporal expression patterns of known AMPAR auxiliary subunits, providing means for designing brain region-selective compounds. Here we report a high-throughput screening-based pipeline that can identify compounds that are selective for GluA2-CNIH3 and GluA2-stargazin complexes. These compounds will help us build upon the growing library of AMPAR-auxiliary subunit specific inhibitors, which have thus far all been targeted to TARP γ-8. We used a cell-based assay combined with a voltage-sensitive dye (VSD) to identify changes in glutamate-gated cation flow across the membranes of HEK cells co-expressing GluA2 and an auxiliary subunit. We then used a calcium flux assay to further validate hits picked from the VSD assay. VU0612951 and VU0627849 are candidate compounds from the initial screen that were identified as negative and positive allosteric modulators (NAM and PAM), respectively. They both have lower IC50/EC50s on complexes containing stargazin and CNIH3 than GSG1L or the AMPAR alone. We have also identified a candidate compound, VU0539491, that has NAM activity in GluA2(R)-CNIH3 and GluA2(Q) complexes and PAM activity in GluA2(Q)-GSG1L complexes.